BY STEN STOVALL
LONDON—AstraZeneca PLC's anticholesterol medicine Crestor failed to beat its top rival, Pfizer Inc.'s Lipitor, in a key clinical trial, hurting chances the British company's top drug can boost its sales when the world's best-selling medicine goes generic and sending its shares lower.
In an effort to differentiate Crestor from Lipitor, AstraZeneca initiated a trial, called Saturn, hoping its drug would have a better impact on patients with clogged arteries, or atherosclerosis, than Lipitor.
via online.wsj.com
No comments:
Post a Comment